Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

Table 6 Treatment-related adverse events, n (%)

Adverse events	All				Grade ≥ 3
	F	R	FP	RP	F	R	FP	RP
Hand-foot skin reaction	9 (12.9)	18 (26.9)	14 (14.7)	26 (32.1)	2 (2.9)	5 (7.5)	1 (1.1)	3 (3.7)
Hypertension	14 (20.0)	8 (11.9)	27 (28.4)	11 (13.6)	5 (7.1)	2 (3.0)	5 (5.3)	1 (1.2)
Fatigue	2 (2.9)	3 (4.5)	5 (5.3)	10 (12.3)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)
Bleeding	2 (2.9)	2 (3.0)	1 (1.1)	3 (3.7)	1 (1.4)	2 (3.0)	0 (0.0)	1 (1.2)
Weight loss	1 (1.4)	3 (4.5)	5 (5.3)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fever	7 (10.0)	4 (6.0)	8 (8.4)	13 (16.0)	2 (2.9)	1 (1.5)	1 (1.1)	1 (1.2)
Oral mucositis	5 (7.1)	3 (4.5)	4 (4.2)	4 (4.9)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
Hoarseness	2 (2.9)	1 (1.5)	3 (3.2)	2 (2.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hematuria	9 (12.9)	6 (9.0)	15 (15.8)	12 (14.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Proteinuria	10 (14.3)	9 (13.4)	21 (22.1)	10 (12.3)	1 (1.4)	0 (0.0)	2 (2.1)	0 (0.0)
Diarrhea	6 (8.6)	9 (13.4)	10 (10.5)	10 (12.3)	0 (0.0)	1 (1.5)	0 (0.0)	1 (1.2)
Constipation	5 (7.1)	7 (10.4)	12 (12.6)	8 (9.9)	1 (1.4)	1 (1.5)	0 (0.0)	0 (0.0)
Nausea/Vomiting	14 (20.0)	15 (22.4)	27 (28.4)	21 (25.9)	1 (1.4)	3 (4.5)	1 (1.1)	1 (1.2)
Hyperthyroidism	2 (2.9)	1 (1.5)	6 (6.3)	3 (3.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypothyroidism	3 (4.3)	0 (0.0)	25 (26.3)	13 (16.0)	0 (0.0)	0 (0.0)	2 (2.1)	0 (0.0)
ALT/AST elevation	14 (20.0)	19 (28.4)	19 (20.0)	28 (34.6)	2 (2.9)	5 (7.5)	4 (4.2)	8 (9.9)
Myocardial enzyme elevation	2 (2.9)	3 (4.5)	12 (12.6)	14 (17.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)

ALT: Alanine transaminase; AST: Aspartate transaminase; F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors.